|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Although the proinvasive capacity of PRL-3 has been validated in multiple types of cancer, its impact on colorectal cancer progression and the underlying mechanisms remain poorly understood.
|
30498084 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
PRL-3 genomic gain was identified in 18 (41 %) of the liver metastasis tumors, and this frequency of gain was significantly increased as compared to that of the corresponding primary CRCs (11 %) (p = 0.001).
|
26563151 |
2016 |
|
Primary malignant neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Although the proinvasive capacity of PRL-3 has been validated in multiple types of cancer, its impact on colorectal cancer progression and the underlying mechanisms remain poorly understood.
|
30498084 |
2019 |
|
Secondary malignant neoplasm of liver
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
A genomic gain in PRL-3 was the most frequent gain in the liver metastases (P=0.004) and was partially redundant with a c-myc genomic gain.
|
30655893 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Targeting PRL-3 may thus be a useful strategy to impede cancer cell invasion and metastasis.
|
17409395 |
2007 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PRL-3 transgenic mice exhibit hallmarks of telomere deprotection and senescence and are susceptible to dextran sodium sulfate-induced colon malignancy.
|
28482095 |
2017 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Recently, several studies on PRL-3 protein in other types of cancer have been published.
|
21291404 |
2011 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Protein tyrosine phosphatase type IVA member 3 (PTP4A3/PRL-3), a metastasis-associated phosphatase, plays multiple roles in cancer metastasis.
|
23064776 |
2013 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This study reveals a new insight into the role of PRL-3 in priming tumor progression and shows that PRL may represent an attractive target for therapeutic intervention in cancer.
|
18281492 |
2008 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this review, we summarize current knowledge of the role of PRL-3 in cancer and the molecular mechanisms involved.
|
31207239 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our findings provide direct evidence that PRL-3 may be involved in triggering angiogenesis and establishing microvasculature and it may serve as an attractive therapeutic target with respect to both angiogenesis and cancer metastasis.
|
17018620 |
2006 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The protein tyrosine phosphatase PRL-3 plays an important role in cancer cell migration, invasion and metastasis.
|
28980126 |
2017 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PRL-3 had been found to be involved in tumorigenesis in various malignancies.
|
26041460 |
2016 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
PRL-3 improves colorectal cancer cell proliferation and invasion through IL-8 mediated glycolysis metabolism.
|
28791350 |
2017 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
KCNN4 channels participate in the EMT induced by PRL-3 in colorectal cancer.
|
23572150 |
2013 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, whether TAMs participate in the progression and metastasis of CRC induced by PRL-3 remains unknown.
|
24885636 |
2014 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
PRL-3 genomic gain was identified in 18 (41 %) of the liver metastasis tumors, and this frequency of gain was significantly increased as compared to that of the corresponding primary CRCs (11 %) (p = 0.001).
|
26563151 |
2016 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
PRL-3 seems to be an adequate marker in diagnosing the stage of tumor advancement for various types of carcinomas, especially for colorectal carcinoma investigated thoroughly in this study.
|
21291404 |
2011 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we found that PRL-3 could also promote EMT in a colorectal cancer cell model SW480 with deficient E-cadherin expression in vivo and in vitro.
|
19440036 |
2009 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overall, the findings indicate that PRL‑3 promotes CRC cell invasion and metastasis by activating MAPK pathways in TAMs to initiate the EMT, and PRL‑3 promotes angiogenesis by activating the NF‑κB pathway in CRC cells.
|
30864736 |
2019 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Stathmin has been identified as a downstream target of PRL-3 in colorectal cancer.
|
31546234 |
2019 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, PRL-3 (also known as PTP4A3), a tyrosine phosphatase located on 8q24.3, is amplified in colorectal cancer metastasis.
|
15750208 |
2005 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our data first reveal transcriptional factor Snail as a key regulator of PRL-3 in CRC.
|
21811102 |
2011 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data suggest that the PRL-3 gene is important for colorectal cancer metastasis and provide a new therapeutic target for these intractable lesions.
|
11598267 |
2001 |
|
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
PRL-3 and E-cadherin exhibit interactions in gastric cancer and are involved in the formation of lymph node metastases.
|
24696260 |
2014 |